Format

Send to

Choose Destination
Rheumatology (Oxford). 2013 Aug;52(8):1397-403. doi: 10.1093/rheumatology/kes388. Epub 2013 Jan 12.

GAPSS: the Global Anti-Phospholipid Syndrome Score.

Author information

1
Lupus Research Unit, The Rayne Institute, Division of Women's Health, King's College London, London SE1 7EH, UK.

Abstract

OBJECTIVE:

To develop and validate a risk score [global APS score (GAPSS)] derived from the combination of independent risk for thrombosis and pregnancy loss (PL), taking into account the aPL profile, conventional cardiovascular risk factors and the autoimmune antibody profile.

METHODS:

This cross-sectional study included 211 consecutive SLE patients. Data on clinical manifestations, conventional cardiovascular risk factors, aPL profile, ANAs, ENA and anti-dsDNA were collected. Long-term low-dose aspirin, oral anticoagulant and HCQ treatment were also included in the analysis. Patients were randomly divided into two sets by a computer-generated randomized list. We developed GAPSS in the first set of patients (n = 106), assigning the risk factors identified by multivariate analysis weighted points proportional to the β-regression coefficient values. GAPSS was validated in the second set of patients (n = 105). The relationship between GAPPS and thrombosis and/or PL was analysed.

RESULTS:

In the first set, higher values of GAPSS were seen in patients who experienced thrombosis and/or PL compared with those without clinical events [GAPSS 9.3 (4.8) (range 1-19) and 5.3 (4) (range 0-16), P < 0.001]. Also taken separately, patients who experienced thrombosis or PL showed higher GAPSS compared with those without clinical events [GAPSS 9.6 (4.8) (range 1-19) vs 4.9 (5) (range 0-14), P = 0.027 for thrombosis; 7.3 (5) vs 3.9 (5.1) (range 0-16), P = 0.024 for PL, respectively]. In the second set, the results were similar, with statistically higher values of GAPSS in patients with a clinical history of thrombosis and/or PL compared with those without events [GAPSS 9.5 (5.6) (range 0-20) and 3.9 (4.1) (range 0-17), P < 0.001). Higher values were also seen when subclassifying the patients according to the clinical manifestation, thrombosis or PL [GAPSS 9.5 (5.6) (range 0-20) vs 4.8 (5.4) (range 0-17), P = 0.036 for thrombosis; 7.9 (3.3) vs 3.8 (5.4) (range 0-16), P = 0.037 for PL, respectively).

CONCLUSION:

These data propose a substantial improvement in risk prediction of thrombosis or PL in SLE based on assessment of the GAPSS, a quantitative scoring system.

KEYWORDS:

Hughes syndrome; antiphospholipid antibodies; pregnancy loss; prothrombin; thrombosis

PMID:
23315788
DOI:
10.1093/rheumatology/kes388
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for University of Turin Instituional Repository AperTO
Loading ...
Support Center